RxDoctor Payments DataLook up a doctor →

Ignacio Ripoll, MD

Critical Care (Intensivists) · Virginia Beach, VANPI 1760489363

Payments from drug & device makers

$11,097in general payments, 2019–2025

Across 474 payments — averaging $23.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • Inspire Medical Systems, Inc.$1K
  • Jazz Pharmaceuticals Inc.$1K
  • Harmony Biosciences LLC$874
  • Actelion Pharmaceuticals US, Inc.$611
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$9328%
  • Food & beverage$9,79588%
  • Education$3693%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few critical care (intensivists) providers in Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$138,042
Medicare patients
513
Services billed
1,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$58,081
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$20,984
Breo ElliptaFluticasone/Vilanterol33$17,153
Ambrisentan12$14,956
Budesonide23$8,659
SymbicortBudesonide/Formoterol Fumarate15$5,226
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$5,174
Albuterol Sulfate HfaAlbuterol Sulfate69$2,254
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate87$2,186
Naltrexone Hcl13$773
Azithromycin18$567
Albuterol Sulfate12$213
Prednisone13$201
Metformin Hcl16$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,634$96,21894 claims
AstraZenecaSymbicort$1,433$5,22615 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$49$21312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care (intensivists) providers in Virginiaon file to place this against a meaningful peer group, so we don't.

Other critical care (intensivists) in Virginia Beach

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →